February 2007
Worldwide Biotech;Feb2007, Vol. 19 Issue 2, p1
Trade Publication
The article reports that Lipoxen PLC, a London, England-based biopharmaceutical company, has entered into an exclusive $75 million worth of contract with a subsidiary of Baxter International Inc. to develop improved, longer-acting forms of blood clotting factors. Hartmut J. Ehrlich, vice president for Baxter's global research and development, said that the agreement furthers Baxter's legacy of scientific innovation in the area of blood-free recombinant protein processing.


Related Articles

  • Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A.  // Biomedical Market Newsletter;1/7/2012, Vol. 21, p1 

    The article offers information on the initiation of phase 1 clinical trial for Baxter International Inc.'s investigational drug BAX 855, it is a longer acting form of a full-length recombinant factor VIII (rFVIII) used for treatment of patients suffering from Hemophilia A. The phase 1 clinical...

  • Baxter Will Apply Lipoxen's Drug Delivery Technology. Bush, Laura // BioPharm International;Jan2007, Vol. 20 Issue 1, p12 

    The article reports on Lipoxen PLC's decision to license its "PolyXen" drug delivery technology to Baxter International Inc. to develop improved, longer-acting forms of Baxter's blood-clotting factors, such as Factor VIII. The PolyXen technology is based on linking or conjugating a naturally...

  • Darbepoetin Alfa: A Review of its Use in the Treatment of Anaemia in Patients with Cancer Receiving Chemotherapy. Siddiqui, M. Asif A.; Keating, Gillian M. // Drugs;2006, Vol. 66 Issue 7, p997 

    Darbepoetin alfa (Aranesp) is an analogue of recombinant human erythropoietin (rHuEPO) produced using recombinant DNA technology. The high number of sialic acid moieties in darbepoetin alfa results in a prolonged half-life and enhanced in vivo biological activity compared with rHuEPO (as...

  • FROM THE LAB.  // Medical Technology & Devices Week;6/25/2007, Vol. 5 Issue 26, p1 

    The article reports on the licensing agreements signed by Baxter International with Intercytex and Spinal Restoration to evaluate the use of the firm's fibrin sealant Tisseel in regenerative medicine therapies. Tisseel will be used by Intercytex in the development of its two products. Spinal...

  • Baxter, Cell Therapeutics Sign JAK[ed] Up Myelofibrosis Deal. Shaffer, Catherine // BioWorld Today;11/18/2013, Vol. 24 Issue 222, p1 

    The article reports on the 172-million-U.S.-dollar licensing deal between healthcare company Baxter International Inc. and biopharmaceutical company Cell Therapeutics Inc. (CTI) for Baxter's exclusive commercialization of CTI's Janus kinase (JAK) inhibitor, pacritinib outside the U.S. Baxter's...

  • Baxter 3Q Mixed, Profit Inches Up.  // MondayMorning;10/22/2012, Vol. 20 Issue 40, p1 

    The article focuses on the third quarter results as reported by Illinois-based Baxter International Inc. According to the reports, the company's profit rose slightly to 583 million U.S. dollars because of increased sales of cancer drugs and hospital equipment. It further states that the...

  • Infectious Diseases News Round-Up.  // PharmaWatch: Monthly Review;Aug2009, Vol. 8 Issue 8, p21 

    The article offers world news briefs related to the pharmaceutical industry. Baxter International Inc. is developing an A/H1N1 vaccine using its Vero cell culture technology to respond the outbreak of H1N1 influenza. Novartis AG has received requests from over 30 governments for the delivery of...

  • Other News To Note.  // BioWorld Today;5/22/2013, Vol. 24 Issue 98, p3 

    The article offers news briefs in the pharmaceutical industry in the U.S. and Europe as of May 22, 2013. Aradigm Corp. has licensed Grifols SA for the Phase III trial of inhaled ciprofloxacin to treat severe respiratory diseases. Biogen Idec Inc. has submitted a biologics application for its...

  • Nike To Discontinue Livestrong Line.  // WWD: Women's Wear Daily;5/29/2013, Vol. 205 Issue 109, p6 

    The article focuses on the discontinuation of licensing agreement by Nike Inc. with Livestrong Foundation, the cancer charity founded by cyclist Lance Armstrong. It states that the move has resulted from the admission of Armstrong for using performance-enhancing drugs to win the Tour de France...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics